Erasca (ERAS) Company Report

Erasca is focused on developing therapies for RAS-driven cancers, with lead programs ERAS-0015 (a pan-RAS molecular glue) and ERAS-4001 (a pan-KRAS switch II pocket inhibitor).
The AURORAS-1 trial for ERAS-0015 is enrolling rapidly and is on track for a first-half update this year, which will include safety, tolerability, PK, and efficacy data from dozens of patients across multiple tumor types. Early clinical data for ERAS-0015 has shown activity at 8 milligrams QD, representing a 10 to 1 dosing advantage compared to RMC-6236, with mostly low-grade adverse events and linear PK.
The BOREALIS-1 study for ERAS-4001 is on track for a second-half data update this year, which will provide information on safety, tolerability, PK, and early signs of activity.
Erasca holds U.S. composition of matter IP for ERAS-0015 extending to 2043. The company plans to explore combinations of ERAS-0015 with anti-EGFR antibodies in the second half of this year.

1 day ago

Transcript

Erasca Provides Update on RAS-Targeting Pipeline and Clinical Trials

ERAS

New Projects/Investments

Product Launch

Guidance Update

Erasca is advancing two lead programs for RAS-driven cancer: ERAS-0015, a pan-RAS molecular glue, and ERAS-4001, a pan-KRAS switch II pocket inhibitor.
The AURORAS-1 trial for ERAS-0015 is progressing well, with a first-half 2026 data update expected for dozens of patients, covering safety, tolerability, PK, and efficacy across multiple tumor types. Early clinical data showed activity at a 10x lower dose than a competitor, with favorable safety.
The BOREALIS-1 trial for ERAS-4001 is on track for a second-half 2026 data update, providing initial safety, tolerability, PK, and early activity data in dozens of patients.
Erasca holds U.S. composition of matter IP for ERAS-0015 extending to 2043.

1 day ago

Transcript

Erasca Provides Updates on RAS-Targeting Pipeline and Clinical Progress

ERAS

New Projects/Investments

Guidance Update

Erasca is focused on RAS-driven cancer with two lead programs: ERAS-0015, a cyclophilin A binding molecular glue, and ERAS-4001, a pan-KRAS switch II pocket inhibitor.
ERAS-0015 has shown promising early clinical data, demonstrating 10x lower dosing for responses compared to Revolution Medicines' RMC-6236, with linear PK and no dose-limiting toxicities as of early January. A first-half 2026 update from the AURORAS-1 trial is anticipated.
The BOREALIS-1 study for ERAS-4001, a pan-KRAS inhibitor with a unique scaffold, is on track for a second-half 2026 data update. Erasca also plans to explore combinations for ERAS-0015 with an anti-EGFR antibody in the second half of 2026.

1 day ago

Transcript

Erasca secures U.S. patent for ERAS-4001

ERAS

New Projects/Investments

Erasca announced that the U.S. Patent and Trademark Office has issued Patent No. 12,552,813, providing intellectual property protection for its pan-KRAS inhibitor ERAS-4001 and related compositions until at least June 2043.
This patent strengthens the ERAS-4001 program, which is a potentially first-in-class pan-KRAS inhibitor, and expands Erasca's diversified intellectual property strategy for RAS-driven cancers.
The company expects to report initial Phase 1 monotherapy data for ERAS-0015 in the first half of 2026 and for ERAS-4001 in the second half of 2026.

4 days ago

Press Release

Erasca Discusses Pipeline Progress for ERAS-0015 and ERAS-4001

ERAS

New Projects/Investments

Guidance Update

Erasca's pan-RAS molecular glue, ERAS-0015, demonstrates 5- to 10-fold higher potency and an improved pharmacokinetic profile compared to RMC-6236 in preclinical models, with preferential tumor distribution.
In the AURORAS-1 Phase 1 study, ERAS-0015 has shown multiple confirmed and unconfirmed partial responses at 8 milligrams, one-tenth the dose of RMC-6236's first responses, alongside a generally safe and well-tolerated profile.
Erasca anticipates reporting data on dozens of patients from the AURORAS-1 study in the first half of 2026 and initiating dose expansion cohorts in the second half of 2026.
The company's pan-KRAS inhibitor, ERAS-4001, is progressing in the BOREALIS-1 study, with data on dozens of patients expected in the second half of 2026.

Feb 12, 2026, 6:00 PM

Transcript

Erasca discusses pipeline progress for ERAS-0015 and ERAS-4001 at Biotech Summit

ERAS

New Projects/Investments

Guidance Update

Erasca's ERAS-0015 (pan-RAS molecular glue) demonstrated multiple confirmed and unconfirmed partial responses in the AURORAS-1 study at an 8 mg dose, which is one-tenth of the dose where a comparator compound first showed responses. The drug exhibited a generally safe and well-tolerated profile with no dose-limiting toxicities (DLTs) observed.
The company anticipates providing an update on dozens of patients from the AURORAS-1 study in the first half of 2026, focusing on safety, PK, and objective response rate (ORR). Dose expansion cohorts for ERAS-0015 are planned for the second half of 2026, primarily targeting pancreatic and lung cancer.
Erasca's ERAS-4001 (pan-KRAS inhibitor), a Switch Two Pocket binder, had its Investigational New Drug (IND) application cleared in Q2 of last year (2025). Data from its BOREALIS-1 study is expected in the second half of 2026, covering safety, PK, and initial activity.
Erasca is pursuing both pan-RAS (ERAS-0015) and pan-KRAS (ERAS-4001) inhibitors, with the potential to combine them or use them with standard-of-care agents, aiming for differentiated compounds in areas of high unmet need.

Feb 12, 2026, 6:00 PM

Transcript

Erasca Provides Update on Pan-RAS and Pan-KRAS Inhibitor Programs

ERAS

New Projects/Investments

Product Launch

Guidance Update

Erasca's lead pipeline asset, ERAS-0015 (pan-RAS molecular glue), has demonstrated multiple confirmed and unconfirmed partial responses at 8 mg in the AURORAS-1 Phase 1 study, a dose significantly lower than a comparator compound, while maintaining a generally safe and well-tolerated profile.
The company anticipates releasing data on dozens of patients from the AURORAS-1 study for ERAS-0015 in the first half of 2026.
Erasca's pan-KRAS inhibitor, ERAS-4001, is also advancing in the BOREALIS-1 Phase 1 study, with data expected in the second half of 2026.
Erasca aims for a 10 points or higher absolute difference in Overall Response Rate (ORR) for ERAS-0015 to achieve meaningful differentiation from daraxonrasib.

Feb 12, 2026, 6:00 PM

Transcript

Erasca Closes Upsized Public Offering

ERAS

New Projects/Investments

Erasca, Inc. (Nasdaq: ERAS) has closed its previously announced upsized public offering, selling a total of 25,875,000 shares of its common stock.
The shares were sold at a price of $10.00 per share, generating approximately $258.8 million in gross proceeds for the company.
Erasca intends to use the net proceeds to fund the research and development of its product candidates and other development programs, as well as for working capital and other general corporate purposes.

Jan 23, 2026, 9:01 PM

Press Release

Erasca Announces Pricing of Upsized Public Offering

ERAS

New Projects/Investments

Erasca, Inc. announced the pricing of an upsized public offering of 22,500,000 shares of its common stock at $10.00 per share.
The offering is expected to generate gross proceeds of $225.0 million for Erasca, with underwriters having a 30-day option to purchase up to an additional 3,375,000 shares.
The company intends to use the net proceeds to fund research and development of its product candidates and other development programs, as well as for working capital and general corporate purposes.

Jan 22, 2026, 1:54 AM

Press Release

Erasca Announces Proposed Public Offering of Common Stock

ERAS

Erasca, Inc. intends to offer and sell $150.0 million of its common stock in a proposed underwritten public offering.
The company also plans to grant the underwriters a 30-day option to purchase up to an additional $22.5 million of shares of its common stock.
The net proceeds from the offering are intended to fund research and development of product candidates and other development programs, as well as for working capital and general corporate purposes.

Jan 20, 2026, 9:01 PM

Press Release